TNF and colorectal carcinoma: Indeed, we found that astrocyte viability is slightly decreased by TNFα (24%) or LPS (20%) for 24 h but is improved during cotreatment with RSV, LYC, or OLP or significantly enhanced by QRC, ALA, CRC, NAC, or GTE (p ≤ 0.05, 0.01, or 0.001), as compared to CTR or TNFα/LPS-treated samples (Figure 2(a)).